BRZE vs MANH

For growth investors, Braze, Inc.

(BRZE) is the stronger pick with 24. 4% revenue growth year-over-year, versus 3. 7% for Manhattan Associates, Inc. (MANH). Manhattan Associates, Inc. (MANH) offers the better valuation at 38. 3x trailing P/E (25. 7x forward), making it the more compelling value choice. Analysts rate Braze, Inc. (BRZE) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Manhattan Associates, Inc.

is actually cheaper at 25. 7x.

Over the past 5 years, Manhattan Associates, Inc.

(MANH) delivered a total return of +4. 3%, compared to -76. 5% for Braze, Inc. (BRZE). Over 10 years, the gap is even starker: MANH returned +135. 2% versus BRZE's -76. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Manhattan Associates, Inc.

(MANH) is the lower-risk stock at 1. 10β versus Braze, Inc. 's 1. 27β — meaning BRZE is approximately 16% more volatile than MANH relative to the S&P 500. On balance sheet safety, Braze, Inc. (BRZE) carries a lower debt/equity ratio of 13% versus 36% for Manhattan Associates, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Braze, Inc.

(BRZE) is pulling ahead at 24. 4% versus 3. 7% for Manhattan Associates, Inc. (MANH). On earnings-per-share growth, the picture is similar: Manhattan Associates, Inc. grew EPS 2. 6% year-over-year, compared to -19. 6% for Braze, Inc.. Over a 3-year CAGR, BRZE leads at 27. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Manhattan Associates, Inc.

(MANH) is the more profitable company, earning 20. 3% net margin versus -17. 8% for Braze, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MANH leads at 26. 1% versus -19. 6% for BRZE. At the gross margin level — before operating expenses — BRZE leads at 67. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Manhattan Associates, Inc.

(MANH) trades at 25. 7x forward P/E versus 34. 7x for Braze, Inc. — 9. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BRZE: 93. 4% to $42. 44.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Manhattan Associates, Inc.

(MANH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +135. 2% 10Y return). Both have compounded well over 10 years (MANH: +135. 2%, BRZE: -76. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BRZE is a small-cap high-growth stock; MANH is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.